恶性肿瘤患者化疗期间生活质量研究被引量：48

导出

摘要目的评价恶性肿瘤患者化疗期间的生活质量状况。方法采用欧洲癌症研究与治疗组织(EORTC)QLQ-C30 3.0生活质量问卷中文版对112名罹患恶性肿瘤的住院患者进行生活质量评估。结果化疗期间90.2%、82.1%、74.1%、69.6%患者的认知功能、情绪状态、躯体功能和角色功能处于好和非常好的状态。而30.4%和32.1%的患者总体健康状况和社会功能严重受损,评分处于差和非常差的等级。就各项躯体症状而言,几乎所有患者均存在不同程度的疲乏和疼痛。60.7%的患者有中、重度的睡眠障碍和(或)食欲减退。辅助化疗组在整体健康状态和躯体功能、角色功能和情绪状态评分上,高于姑息化疗组(P=0.006,0.014,0.043,0.006);在症状评分、疲乏、恶心呕吐、呼吸困难、食欲减退方面,辅助化疗组优于姑息化疗组(P=0.033,0.04,0.001,0.014);<60岁和≥60岁年龄组在生活质量总体评分、功能评分和症状评分上差异均无显著性(P>0.05)。结论癌症化疗期间患者的认知、情绪、角色、躯体功能大部分处于良好状态,其总体健康状况和社会功能受损,疲乏和疼痛是癌症患者的普遍症状。辅助化疗组在整体健康状态和主要功能症状方面皆优于姑息治疗组;<60岁组与≥60岁组患者的生活质量差别不大。

作者邓晶何江娟钟林徐农

机构地区浙江大学医学院附属第一医院化疗科

出处《实用肿瘤杂志》 CAS 2007年第1期48-50,共3页 Journal of Practical Oncology

关键词肿瘤/药物疗法生活质量问卷

分类号 R730.5 [医药卫生—肿瘤]

引文网络
相关文献

参考文献6

1万崇华,陈明清,张灿珍,汤学良,孟琼,张晓磬.癌症患者生命质量测定量表EORTC QLQ-C30中文版评介[J].实用肿瘤杂志,2005,20(4):353-355. 被引量：1492
2Fayers P,Aaronson NK,Bjordal K,et al.On behalf of the EORTC Quality of Life Study Group.EORTC QLQ-C30 Scoring Manual.ed.3.ISBN 2-930064-22-6[Z].Brussels:EORTC,2001.1-86.
3艾斌,石远凯,何小慧,韩晓红,赵丽雅,周生余,刘鹏,杨建良,张长弓,黄鼎智,秦燕,杨晟.恶性肿瘤患者自体造血干细胞移植后的生活质量[J].中华医学杂志,2005,85(37):2640-2643. 被引量：10
4Worel N,Biener D,Kalhs P,et al.Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation[J].Bone Marrow Transplant,2002,30(9):619-662.
5Balducci L,Cohen HJ,Paul F,et al.Clinical Practice Guidelines in Oncology.Senior Adult Oncology.[DB/OL]Version 1.2005.National Comprehensive Cancer Network.2005.1-38.
6Mock V,Atkinson A,Barsevick A,et al.Clinical Practice Guidelines in Oncology.Cancer-Related Fatigue.[DB/OL]Version 2.2005.National Comprehensive Cancer Network.2005.1-26.

二级参考文献21

1达万明,王在邦,钟建庭,刘源.自体骨髓移植后患者生存质量的动态调研[J].中华血液学杂志,1994,15(12):638-640. 被引量：12
2Johnson JR,Temple R. Food and drug administration requirements for approval of new anti-cancer drugs[J]. Cancer Treat Rep, 1985,69(10) : 1155-1157.
3Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30:a quality of life instrument for use in international clinical trials in oncology [J]. J Natl Cancer Inst, 1993,85 (5) : 365-376.
4Aaronson NK, Cull A, Kaasa S, et al. The EORTC modular approach to quality of life assessment in ontology [J]. Int J Ment Health, 1994,23 (4):75-96.
5Fayers PM, Hopwood P, Harvey A, et al. On behalf of EORTC Quality of Life Study Group. The EORTC QLQ-C30 Scoring Manual 3rd ed. Brussels: EORTC, 2001.
6Worel N, Biener D, Kalhs P, et al. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation.Bone Marrow Transplant, 2002,30:619-662.
7Bunnell CA, Silver C, Winer EP. Quality of life after bone marrow transplantation. In Armitage JO, Antman KH, eds. High-dose caner therapy: pharmacology, hematopoietins, stem cells. 3rd ed. Philadelphia: Lippincott Williasms & Wilkins, 2000. 153-166.
8Aaronson NK, Ahmedzai S, Bergman B, et al. The European Orgnisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 1993, 85: 365-376.
9Hjermstad MJ, Holte H, Evensen S, et al. Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? Bone Marrow Transplant, 1999, 24, 911-918.
10Wettergren L, Langius A, Bjorkholm M, et al. Physical and psychosocial functioning in patients undergoing Autologous bone marrow transplantation-a prospective study. Bone Marrow transplant,1997, 20:497-502.